Valicenti Advisory Services Inc. Sells 375 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Valicenti Advisory Services Inc. trimmed its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 1.1% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 33,736 shares of the medical equipment provider’s stock after selling 375 shares during the quarter. Intuitive Surgical makes up 3.7% of Valicenti Advisory Services Inc.’s portfolio, making the stock its 6th biggest holding. Valicenti Advisory Services Inc.’s holdings in Intuitive Surgical were worth $11,536,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. HHM Wealth Advisors LLC raised its holdings in Intuitive Surgical by 1,314.3% in the 1st quarter. HHM Wealth Advisors LLC now owns 99 shares of the medical equipment provider’s stock valued at $25,000 after acquiring an additional 92 shares during the last quarter. Bogart Wealth LLC increased its stake in Intuitive Surgical by 721.4% in the first quarter. Bogart Wealth LLC now owns 115 shares of the medical equipment provider’s stock valued at $29,000 after purchasing an additional 101 shares during the last quarter. Barrett & Company Inc. purchased a new position in Intuitive Surgical during the first quarter worth about $30,000. Strategic Investment Solutions Inc. IL acquired a new stake in Intuitive Surgical in the 1st quarter worth about $39,000. Finally, Addison Advisors LLC grew its holdings in Intuitive Surgical by 1,837.5% in the 1st quarter. Addison Advisors LLC now owns 155 shares of the medical equipment provider’s stock valued at $40,000 after buying an additional 147 shares during the period. 82.91% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Intuitive Surgical

In other Intuitive Surgical news, EVP Robert Desantis sold 2,535 shares of Intuitive Surgical stock in a transaction on Tuesday, July 25th. The shares were sold at an average price of $323.26, for a total value of $819,464.10. Following the completion of the transaction, the executive vice president now owns 7,259 shares of the company’s stock, valued at $2,346,544.34. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In other news, EVP Robert Desantis sold 2,535 shares of the firm’s stock in a transaction dated Tuesday, July 25th. The shares were sold at an average price of $323.26, for a total value of $819,464.10. Following the transaction, the executive vice president now directly owns 7,259 shares in the company, valued at approximately $2,346,544.34. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Alan J. Levy sold 2,000 shares of the stock in a transaction dated Monday, August 7th. The stock was sold at an average price of $310.00, for a total transaction of $620,000.00. Following the sale, the director now owns 25,319 shares in the company, valued at approximately $7,848,890. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 60,309 shares of company stock valued at $19,649,321. Corporate insiders own 0.90% of the company’s stock.

Intuitive Surgical Stock Down 0.2 %

Shares of ISRG traded down $0.54 during midday trading on Tuesday, hitting $297.63. The company had a trading volume of 51,966 shares, compared to its average volume of 1,692,815. Intuitive Surgical, Inc. has a 52 week low of $180.07 and a 52 week high of $358.07. The company’s 50 day moving average price is $314.56 and its 200 day moving average price is $298.07. The stock has a market cap of $104.59 billion, a price-to-earnings ratio of 74.73, a PEG ratio of 4.15 and a beta of 1.30.

Intuitive Surgical (NASDAQ:ISRG) last announced its quarterly earnings data on Thursday, July 20th. The medical equipment provider reported $1.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.33 by $0.09. The firm had revenue of $1.76 billion for the quarter, compared to analysts’ expectations of $1.74 billion. Intuitive Surgical had a return on equity of 12.41% and a net margin of 21.38%. Intuitive Surgical’s revenue for the quarter was up 15.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.85 earnings per share. Equities analysts anticipate that Intuitive Surgical, Inc. will post 4.53 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the stock. Piper Sandler raised their target price on shares of Intuitive Surgical from $315.00 to $385.00 and gave the stock an “overweight” rating in a research report on Friday, July 21st. Barclays upped their price objective on Intuitive Surgical from $314.00 to $385.00 and gave the stock an “overweight” rating in a report on Monday, July 24th. JPMorgan Chase & Co. lifted their target price on Intuitive Surgical from $335.00 to $365.00 and gave the company an “overweight” rating in a report on Friday, July 21st. Wells Fargo & Company upped their price target on Intuitive Surgical from $310.00 to $386.00 and gave the stock an “overweight” rating in a research note on Friday, July 21st. Finally, Truist Financial lifted their price objective on Intuitive Surgical from $347.00 to $400.00 in a research note on Wednesday, July 19th. Five analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $343.10.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System to enable complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.